New hope for kids with seizures: cenobamate trial launches

NCT ID NCT07594158

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a drug called cenobamate in 20 Japanese children aged 2 to 17 who have partial-onset seizures that are not fully controlled by current treatments. The main goal is to see if the drug is safe and tolerable. Participants will take cenobamate tablets daily, with doses adjusted based on their response.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Cenobamate (tablet)

What this could lead to

If successful, cenobamate could offer a new treatment option to help control partial seizures in children with epilepsy.

What could go wrong

This is a small, open-label study with only 20 participants, so results may not apply broadly. Side effects are possible, and the drug may not work for everyone.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PARTIAL EPILEPSY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

focal epilepsy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Japan Red Cross Fukuoka Hospital

    RECRUITING

    Fukuoka, Japan